The FIGHT DMD Trial

The FIGHT DMD Trial The FIGHT DMD trial is a phase 2 randomized, placebo-controlled study evaluating an oral medication c You can read more about these studies here.

Fibrosis is the process of replacing normal tissue with scarred tissue which cannot function like normal tissue. Scarring of the heart is part of the disease process in Duchenne. Ifetroban is being studied as a potential anti-fibrotic medication in several diseases but is not approved for and has never been studied in DMD patients. Studies in animal models of DMD showed oral ifetroban can prevent the scarring in the heart associated with Duchenne and improve survival compared to placebo.

The Cumberland team would like to thank the conference organizers and everyone who stopped by our booth at PPMD 2026 in ...
07/15/2026

The Cumberland team would like to thank the conference organizers and everyone who stopped by our booth at PPMD 2026 in Orlando to learn about our work and connect with us. We enjoyed meeting families, researchers and others to talk about ifetroban and the FIGHT DMD trial.

06/26/2026

Happening this morning! ⏰
Dr. Chet Villa takes the stage at 10:30 AM in the "Cardiac Research Therapies: Investigational & Repurposed" session to present the FIGHT DMD trial and our ifetroban program for the cardiomyopathy associated with Duchenne in Veracruz C Hall. Come join us, then stop by booth #1 in the Exhibit Hall afterward to keep the conversation going.

06/25/2026

It's almost time. 🧡
PPMD 2026 starts today in Orlando, and our team is packed and ready. Stop by booth #1 to say hello, ask about the FIGHT DMD trial, and meet the people behind the ifetroban program. We'll be sharing updates from the floor all weekend, so follow along here.
To the whole Duchenne community heading to Coronado Springs — safe travels, and we can't wait to see you.

Attending 's 2026 Annual Conference in Orlando? Stop by Booth #1 to meet our team, learn about our work, and connect wi...
06/24/2026

Attending 's 2026 Annual Conference in Orlando? Stop by Booth #1 to meet our team, learn about our work, and connect with us throughout the event.
We look forward to seeing you there!

06/23/2026

Before we head to Orlando, a thank-you that's overdue 🙏
None of this happens without our clinical trial sites. The coordinators, investigators, and study teams who schedule the cardiac MRIs, answer our endless queries, and enter the data are the reason the FIGHT DMD trial keeps moving — and the reason we have anything to share at PPMD at all.
To every site team carrying this work this year: thank you. We're grateful to be doing it alongside you, and we'll be carrying that gratitude with us into the conference.

06/22/2026

Meet our PPMD presenter 👋
We're glad to share that Chet R. Villa, MD will be presenting on behalf of the FIGHT DMD trial in Orlando. Dr. Villa is a pediatric cardiologist at Cincinnati Children's Hospital Medical Center and a site investigator on the study, which means he brings both the clinical research view and the everyday experience of caring for boys and young men with Duchenne.
He'll be speaking during the "Cardiac Research Therapies: Investigational & Repurposed" session on Friday, June 26 from 10:30 to 11:00 AM in Veracruz C, sharing the FIGHT DMD trial and what we have learned about ifetroban and the DMD heart. If you'll be at PPMD, we'd love to have you in the room.

We're proud to support 's 2026 Annual Conference, taking place June 25–27 in Orlando, FL, as a Bronze Sponsor. We look f...
06/19/2026

We're proud to support 's 2026 Annual Conference, taking place June 25–27 in Orlando, FL, as a Bronze Sponsor. We look forward to connecting with families, advocates, clinicians, and community members dedicated to improving outcomes for those living with and .

Learn more and register: parentprojectmd.org/conference

06/18/2026

Big news worth sharing with our DMD community 🎉
Earlier this year, the FDA granted Fast Track Designation to ifetroban for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy. Fast Track means we work more closely and more often with the FDA as we move the program forward — and it follows the Orphan Drug and Rare Pediatric Disease designations ifetroban has already received.
Heart disease is the leading cause of death in Duchenne, and this milestone reflects how seriously the cardiac side of DMD is being taken. Thank you to the families, clinicians, and advocates who continue to push this work forward with us. 💙

Address

Nashville, TN

Website

Alerts

Be the first to know and let us send you an email when The FIGHT DMD Trial posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category